Altimmune, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
March 27, 2024 at 04:35 pm IST
Share
Altimmune, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported sales was USD 0.037 million compared to negative sales of USD 0.11 million a year ago. Net loss was USD 31.64 million compared to USD 21.66 million a year ago. Basic loss per share from continuing operations was USD 0.54 compared to USD 0.43 a year ago.
For the full year, sales was USD 0.426 million compared to negative sales of USD 0.068 million a year ago. Net loss was USD 88.45 million compared to USD 84.71 million a year ago. Basic loss per share from continuing operations was USD 1.66 compared to USD 1.81 a year ago.
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Companyâs wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.
ALTIMMUNE, INC. 
